Fox Run Management L.L.C. bought a new position in shares of GlaxoSmithKline plc (NYSE:GSK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,389 shares of the pharmaceutical company’s stock, valued at approximately $262,000.
Several other hedge funds have also recently added to or reduced their stakes in GSK. Principal Financial Group Inc. purchased a new position in GlaxoSmithKline in the second quarter valued at approximately $602,000. Dimensional Fund Advisors LP increased its stake in GlaxoSmithKline by 9.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,592,604 shares of the pharmaceutical company’s stock valued at $68,673,000 after purchasing an additional 131,284 shares during the last quarter. Veritable L.P. increased its stake in GlaxoSmithKline by 6.1% in the second quarter. Veritable L.P. now owns 8,116 shares of the pharmaceutical company’s stock valued at $350,000 after purchasing an additional 465 shares during the last quarter. Institute for Wealth Management LLC. purchased a new position in GlaxoSmithKline in the second quarter valued at approximately $739,000. Finally, Fred Alger Management Inc. increased its stake in GlaxoSmithKline by 26.4% in the second quarter. Fred Alger Management Inc. now owns 39,236 shares of the pharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 8,185 shares during the last quarter. Hedge funds and other institutional investors own 9.52% of the company’s stock.
GSK has been the topic of a number of research reports. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Investec lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Finally, TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $38.57.
GlaxoSmithKline plc (NYSE GSK) opened at $36.27 on Tuesday. GlaxoSmithKline plc has a 52-week low of $34.52 and a 52-week high of $44.53. The firm has a market capitalization of $88,020.00, a price-to-earnings ratio of 42.17, a PEG ratio of 2.33 and a beta of 0.98. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.39.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. The business had revenue of $10.14 billion during the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. sell-side analysts forecast that GlaxoSmithKline plc will post 2.82 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be given a dividend of $0.633 per share. This represents a $2.53 dividend on an annualized basis and a yield of 6.98%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 237.21%.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/7389-shares-in-glaxosmithkline-plc-gsk-acquired-by-fox-run-management-l-l-c.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.